U.S. Food and Drug Administration (“FDA”) Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi™, and assigned a PDUFA target action date of February 28, 2027  If approved, Oxnimbi has the potential to become the first oral pharmacologic therapy designed to address the neuromuscular root cause of upper airway collapse for the millions of people living with OSA  Strengthened the Company’s leadership team with several key appointments   Completed its upsized initial public offering for gross proceeds of $220.8 million and its common stock began trading on the Nasdaq Global Select Market CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) — Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies...

Quarterly Results Reflect Improved Profitability, First Day® Complete Growth and Continued Balance Sheet Progress Net Income (Loss) Improves 29% and Adjusted EBITDA Improves 19% Year-Over-Year Fall 2026 First Day® Complete Expected to Reach More Than 1.43 Million Students, 26% More than Fall 2025 Company Reiterates Fiscal 2027 Outlook FLORHAM PARK, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) — Barnes & Noble Education, Inc. (NYSE: BNED) (“Barnes & Noble Education,” “BNED,” the “Company,” “we,” “us” or “our”), a leading solutions provider for the education industry, today reported financial results for the fiscal first quarter ended August 1, 2026. During the first quarter, the Company delivered year-over-year improvement across its key operating and financial measures, including revenue, comparable store sales,...

FLEURY MICHON Résultats S1 2026 : Sur le premier semestre 2026, Fleury Michon affiche une croissance de son chiffre d’affaires de 3,5% par rapport à la même période en 2025. Cette performance est portée par la hausse du chiffre d’affaires en GMS France (+2,8 %), liée principalement à des gains de parts de marché. Elle est soutenue par une solide croissance à +6,6 % du pôle International. Après un exercice 2025 fortement dégradé par la crise liée au cours de la volaille, le taux de marge opérationnelle du groupe se rétablit à 2,6%. Pouzauges, le mardi 08 septembre 2026, à 18 heuresAu cours du premier semestre 2026, Fleury Michon enregistre un chiffre d’affaires en croissance de +3,5% par rapport au premier semestre 2025. Les activités GMS sont en croissance de +2,8%. Cette croissance est tirée principalement par nos gains de parts de...

J.P. Morgan Structured Products B.V. 2026 Interim Financial StatementsAttachment2026 – JPMSP BV (Interim) – FINAL VERSION

ATHENS, Greece, Sept. 08, 2026 (GLOBE NEWSWIRE) — Dynagas LNG Partners LP (NYSE: DLNG) (the “Partnership”), an owner of liquefied natural gas (“LNG”) carriers, today announced its results for the three and six months ended June 30, 2026. Half year Highlights:Net Income and Earnings per common unit (basic and diluted) of $33.4 million and $0.82, respectively; Adjusted Net Income(1) of $28.2 million and Adjusted Earnings per common unit(1) (basic and diluted) of $0.68; Adjusted EBITDA(1) of $51.9 million; and 95.7% fleet utilization(2).Quarter Highlights:Net Income and Earnings per common unit (basic and diluted) of $16.0 million and $0.39, respectively; Adjusted Net Income(1) of $15.8 million and Adjusted Earnings per common unit(1) (basic and diluted) of $0.39; Adjusted EBITDA(1) of $27.6 million; 96.2% fleet utilization(2); The...

Company Anticipates $7M-$8M FY’26 Adjusted Gross Profit(1), vs. Prior Guidance $5M-$7M Company Anticipates Adjusted Net Operating Cash Flow(4) to Turn Positive in Q3’26 Company Anticipates Generating Positive Core Operating Earnings(3) in Q3’26 Company Announces New $20M Stock Buyback Authorization DALLAS, Sept. 08, 2026 (GLOBE NEWSWIRE) — Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), the first U.S. publicly listed DeFi company building on Hyperliquid, today raised its full-year 2026 guidance and provided new Q3’26 guidance driven by its core operations exceeding management’s prior expectations. In addition, the Company is launching a new $20 million share buyback program. “In the past few weeks, our DeFi businesses have accelerated,” said Hyunsu Jung, CEO of Hyperion DeFi. Mr. Jung continued, “We have now...

RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) — Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for H1 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes. The open-label Phase IIa study enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed following standard therapies. Fourteen patients received Namodenoson as third-line treatment, five as second-line treatment, and one as fourth-line treatment. Namodenoson was well...

Raises Midpoint of Outlook For Fiscal 2026 Adjusted EPS and Increases Free Cash Flow ExpectationsRevenue increased 4.2% to a quarterly record of $2.3 billion, including organic growth of 2.1% and acquisition-related growth of 2.1% Net income increased 19% to $49.7 million, or $0.84 per diluted share, as compared to $41.8 million, or $0.67, in the prior year Adjusted net income grew 19% to $61.5 million, or $1.04 per diluted share, versus $51.7 million, or $0.82, in the prior year Adjusted EBITDA improved 11% to $139.6 million, versus $125.8 million last year Operating cash flow was $146.8 million and free cash flow totaled $128.4 million Through nine months, operating cash flow was $275.0 million and free cash flow was $199.6 million, both significantly improved over the prior year period Company raises outlook for full year adjusted...

Paris, 8 September 2026, 9.00am Rubis announces today that its half-year financial report as of 30 June 2026 is available and has been filed with the Autorité des Marchés Financiers (the French Financial Markets Authority – AMF). The 2026 half-year financial report can be downloaded from Rubis’ website (www.rubis.fr), in the “Investors – Regulated information – Half-year financial report” section.    This document is a translation of the original French document and is provided for information purposes only. In all matters of interpretation of information, views or opinions expressed therein, the original French version takes precedence over this translation  Contact  RUBIS – Legal Department  Tel: +(33) 1 44 17 95 95AttachmentRubis: Availability of the 2026 half-year financial report

 Paris, 08 September 2026, 7:00amEBITDA at €434m, +18% yoy reflecting sustained demand, disciplined execution and optimised inventory management in a volatile and high oil price context, highlighting the Group’s ability to consistently deliver strong results across challenging market conditions. Net income Group share of €191m, +17% yoy in line with operational performance. Cash flow generation – Adjusted cash flow from operating activities1 at €223m in H1 2026 (vs €276m in H1 2025) reflecting higher working capital requirements amid higher oil prices. Corporate Net Financial Debt to EBITDA ratio2 of 1.3x at Jun-2026 vs 1.4x in H1 2025, confirming the robustness of Rubis balance sheet – Total Net Financial Debt3 of €1,466m. 2026 EBITDA guidance upgraded to €775m to €825m (previously €740m-€790m) underpinned by strong first-half...